Mylan rejected TEVA offer

Mylan pharma rejected TEVA pharma offer on the base of cash -and-stock buying offer. TEVA given buyout offer @ rate of $82 per share. But MYLAN rejected offer. In this scenario mylan share price traded at $72.50 on monday with the loss of $3.76

NATCO MYLAN TEVA and COPAXONE

Teva Generic medical industry from Israel. Recently this company passed a resolution in their board of directors meeting, to purchase US based another generic medical industry, that is Mylan. 

These companies are top two companies of world in generic medical field.

Teva wanted to close this deal  $82 for share. Offer value is Rs.2,50,000 Cr ($,000 Cr Dollars) 

As per Teva chairmen Peter burg Teva board of directors passed a resolution unanimously. 

But Mylan not responded.

It’s a Big Deal :

If Teva purchase mylan, it’s an a big deal in pharma industry. This two companies yearly earning is $ 3,000 Cr in Rs.1,80,000 Cr. If Teva deal completes with Mylan, Teva Reach first place world wide in generic medicine industry.  At right now US based mylan is in second place in world wide.

Ranbaxy reached world's 5^th place after Sun pharma merge with Ranbaxy. TEVA and Mylan facing big competitions from developing companies like Ranbaxy. Teva feels that if the deal complete with Mylan, then  facing competitions are easy.  Mylan started their activity in India in 2012 under the supervision of Rajiv malik president and Executive director of Mylan. Rajiv Malik is Indian descent.

About TEVA :

Established     : 1901

Place                 : Peta Tikwa, Israil

Net profit          : $ 2,030 Cr

Shares Listed : New york Stock Exchange, Tel Aviv Stock Exchange

Working Are   : Israil, South America, North America, Iropa

Placed at world’s first place under generic Medicine Companies

About Mylan :

Established     : 1961

Place                 : Pensilinia, USA

Net Profit          : $ 770 Cr

Shares Listed : Nasdac

Working Are    : North America, Iropa, Asia Pacipic, Africa and middle east

Placed at world’s Second place under generic Medicine Companies

  NATCO crushing :

If this deal completes NATCO pharma may face some patent problems on ‘COPAXONE MEDICINE. 

With this issue only Natco pharma stock price was gone up to  6% below in 22^nd April 2015 trading. At end of the session natco phrma stock price closed with 4% loss at Rs. 2,064/-

‘COPAXONE’ medicene have full demand world wide which is using in nerve related diseases treatment.  In 2014 COPAXONE sales value is Rs.26,460 Cr.  TEVA get 50% profit with copaxone sales in total TEVA’s profit. 

With this figures we can understand what is the role of COPAXONE in TEVA Pharma. COPAXONE patent rights are ending 2015 September, Which patent rights have TEVA.

Natco along with Mylan got a world wide permission for generic version of COPAXONE.  TEVA reached some courts. Some courts given judgement in the favor of NATCO. But one case is still pending in USA courts. NATCO got a permission for this product sales in USA through USFDA.

If TEVA completes the deal with mylan. Here one question is raising what will happened in the deal of NATCO and MYLAN on the marketing of COPAXONE.